PFKP is required for chemoresistant phenotype of breast cancer through modulating the formation of CD133+ cancer stem like cells
Abstract Breast cancer is the foremost cause of cancer-related death in women globally, and taxane-anthracycline (TA) combination regimens represent standard frontline chemotherapy. Although widely administered, the pathological complete response rate to TA therapy is less than 30%, and chemoresista...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer
2026-04-01
|
| Colección: | Molecular Biomedicine |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s43556-026-00454-z |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|